Trial Profile
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2016
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Cisplatin; Doxorubicin; Methotrexate; Vinblastine
- Indications Urogenital cancer
- Focus Therapeutic Use
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 13 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 03 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.